If you searched “sermorelin before and after,” you were probably hoping to find side-by-side transformation photos: a leaner waistline, more muscle, firmer skin. We do not publish those images, and we want to be direct about why. dosagepeptide.com is a research-use-only dosage reference, not a supplement marketer, and the honest reality is that the peer-reviewed literature on sermorelin does not contain validated “before-and-after” transformation data of the kind those photos imply.
What the literature does contain is a small, mostly older set of clinical studies that measured specific biological markers over defined timeframes. Instead of testimonials, this page lays out what those studies actually documented, and where the evidence runs out.
What the research shows over time
Sermorelin is a synthetic fragment of growth-hormone-releasing hormone (GHRH 1-29). It has a very short half-life of roughly 10-20 minutes in humans and works indirectly, prompting the pituitary to release the body’s own growth hormone (GH), which in turn raises insulin-like growth factor 1 (IGF-1) (Esposito, 2003). The measured story unfolds in stages:
- Minutes (acute): a single subcutaneous dose triggers a GH pulse within about 10 minutes that lasts roughly two hours (Khorram, 1997).
- First weeks: in a placebo-controlled trial of 19 healthy older adults, a GHRH(1-29) analog in the sermorelin family raised IGF-1 by about 28% within four weeks (Khorram, 1997).
- Months (adults): across 16 weeks, that same trial found increased skin thickness in both sexes and a modest lean-body-mass gain in men only, with no change in overall body weight, fat mass, or bone density (Khorram, 1997).
- Months (children with GH deficiency): height velocity roughly doubled, but this is a pediatric linear-growth endpoint that says nothing about adult physique (Thorner, 1996; Ogilvy-Stuart, 1997).
| Study (design) | Duration | What was measured |
|---|---|---|
| Khorram, 1997 (RCT, 19 older adults) | 16 weeks | IGF-1 up ~28% by week 4; lean mass up in men only; no change in body weight, fat, or bone density |
| Thorner / Geref, 1996 (multicenter, 110 GH-deficient children) | 12 months | Height velocity rose from 4.1 to 8.0 cm/yr at 6 months (pediatric growth, not adult physique) |
| Ogilvy-Stuart, 1997 (multicenter, 9 children, radiation-induced GHD) | 12 months | Height velocity 3.3 to 6.0 cm/yr, less than standard GH therapy |
| Lindgren, 2016 (retrospective, 122 men) | ~16 months (median) | No significant change in IGF-1, body weight, or body-fat percentage |
| Sigalos, 2017 (retrospective, 14 men) | ~4.5 months | IGF-1 rose 159 to 239 ng/mL, but on combination GHRP + testosterone therapy, very small sample |
It is worth separating the tiers of evidence explicitly. The clinical data above are prospective trials, but most are decades old and enrolled small numbers. The retrospective chart reviews (Lindgren, 2016; Sigalos, 2017) are lower-quality and disagree with each other. There is no controlled trial showing adult cosmetic “transformation,” and the anecdotal before-and-after photos circulating online are not evidence at all.
Realistic expectations
Here is what the data supports: short-term biochemical shifts (a GH pulse, and an IGF-1 rise within a few weeks), accelerated growth velocity in genuinely GH-deficient children, and a modest lean-mass change in men in one small older-adult trial (Khorram, 1997; Thorner, 1996).
Here is what the data does not support: reliable adult fat loss, weight loss, or dramatic body recomposition. The largest real-world series available, 122 men followed for a median of roughly 16 months, found no significant change in IGF-1, body weight, or body-fat percentage (Lindgren, 2016). A dedicated review of growth-hormone secretagogues concluded that clinical efficacy data for these compounds are “largely lacking” (Sinha, 2020).
Individual variation is large, the human samples are tiny, and results depend heavily on baseline hormone status. That is precisely why online before-and-after photos are misleading for a research compound: they are uncontrolled, usually confounded by simultaneous diet, training, testosterone, or other drugs, rarely verified, subject to selection bias (people post successes, not failures), and frequently attached to a sales page.
Safety and legal status
In the older controlled trials, sermorelin-type GHRH analogs were generally well tolerated. Reported signals included transient hyperlipidemia that resolved by study end (Khorram, 1997), mild injection-site reactions, and some impairment of glucose tolerance with repeated dosing in elderly subjects (using a longer-acting pegylated GHRH; Munafo, 2005). A 2026 narrative review of GH/IGF-1-axis peptides catalogs additional class-level concerns: prolactin and cortisol elevations, dysglycemia, fluid retention, joint and muscle aches, and a biologically plausible but unproven mitogenic concern tied to chronically raising IGF-1 (Dominikowski, 2026).
On status: sermorelin was historically studied and used clinically as Geref for pediatric GH-deficiency and for GH-secretion testing. The class carries no regulatory approval for anti-aging, weight-loss, physique, or athletic-performance indications (Dominikowski, 2026; Sinha, 2020). On this site, sermorelin is referenced strictly as a research compound. Nothing here is medical advice, and our references do not claim that any product causes human body transformations.
Dosage reference
If you are here for the actual numbers rather than photos, use our structured reference material. Our Sermorelin dosage chart lays out reconstitution and per-vial figures for laboratory reference, and the peptide dosage calculator converts vial size, diluent volume, and target amount into a syringe reading. These tools are provided for research documentation only, not as instructions for human use.
FAQ
Are there real before-and-after photos of sermorelin?
Not in the scientific literature. Published sermorelin studies measured biochemical markers (GH, IGF-1) and, in children, height velocity, not cosmetic outcomes. The photos you see online are uncontrolled anecdotes, often confounded by other variables and unverifiable, so they cannot be treated as evidence.
How long until changes appear in studies?
Biochemically, IGF-1 rose within about four weeks in an older-adult trial, and structural endpoints such as skin thickness and lean mass were assessed at 16 weeks (Khorram, 1997). In GH-deficient children, growth changes were tracked over 6 to 12 months (Thorner, 1996). These timeframes describe measured markers, not guaranteed personal results.
Does sermorelin cause weight loss or fat loss?
Controlled adult data do not support that claim. The largest real-world series reported no significant change in body weight or body-fat percentage over roughly 16 months (Lindgren, 2016), and one 16-week trial found no change in fat mass (Khorram, 1997).
Research summarized on this page draws on peer-reviewed studies indexed in PubMed and ClinicalTrials.gov, retrieved via PubMed and the Consensus academic search corpus. See the citations below, with DOIs, for the primary sources.
